SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • Abdelmagid SM, Barbe MF, Arango-Hisijara I, Owen TA, Popoff SN, Safadi FF. 2007. Osteoactivin acts as downstream mediator of BMP-2 effects on osteoblast function. J Cell Physiol 210: 2637.
  • Abdelmagid SM, Barbe MF, Rico MC, Salihoglu S, Arango-Hisijara I, Selim AH, Anderson MG, Owen TA, Popoff SN, Safadi FF. 2008. Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function. Exp Cell Res 314: 23342351.
  • Akiyama H, Chaboissier MC, Martin JF, Schedl A, de Crombrugghe B. 2002. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev 16: 28132828.
  • Akiyama H, Kim JE, Nakashima K, Balmes G, Iwai N, Deng JM, Zhang Z, Martin JF, Behringer RR, Nakamura T, de Crombrugghe B. 2005. Osteo-chondroprogenitor cells are derived from Sox9 expressing precursors. Proc Natl Acad Sci USA 102: 1466514670.
  • Anson DS. 2004. The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther 2: 9.
  • Bajada S, Harrison PE, Ashton BA, Cassar-Pullicino VN, Ashammakhi N, Richardson JB. 2007. Successful treatment of refractory tibial nonunion using calcium sulphate and bone marrow stromal cell implantation. J Bone Joint Surg Br 89: 13821386.
  • Banwart JC, Asher MA, Hassanein RS. 1995. Iliac crest bone graft harvest donor site morbidity. A statistical evaluation. Spine 20: 10551060.
  • Bauer G, Dao MA, Case SS, Meyerrose T, Wirthlin L, Zhou P, Wang X, Herrbrich P, Arevalo J, Csik S, Skelton DC, Walker J, Pepper K, Kohn DB, Nolta JA. 2008. In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors. Mol Ther 16: 13081315.
  • Bi W, Deng JM, Zhang Z, Behringer RR, de Crombrugghe B. 1999. Sox9 is required for cartilage formation. Nat Genet 22: 8589.
  • Bianco P, Robey PG. 2001. Stem cells in tissue engineering. Nature 414: 118121.
  • Blum JS, Barry MA, Mikos AG, Jansen JA. 2003. In vivo evaluation of gene therapy vectors in ex vivo-derived marrow stromal cells for bone regeneration in a rat critical-size calvarial defect model. Hum Gene Ther 14: 16891701.
  • Boden SD. 1999. Bioactive factors for bone tissue engineering. Clin Orthop Relat Res 367: S84S94.
  • Bruder SP, Fink DJ, Caplan AI. 1994. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem 56: 283294.
  • Bulte JW, Duncan ID, Frank JA. 2002. In vivo magnetic resonance tracking of magnetically labeled cells after transplantation. J Cereb Blood Flow Metab 22: 899907.
  • Buxton P, Edwards C, Archer CW, Francis-West P. 2001. Growth/differentiation factor-5 (GDF-5) and skeletal development. J Bone Joint Surg Am 83 ( Suppl 1): S23S30.
  • Byers BA, Garcia AJ. 2004. Exogenous Runx2 expression enhances in vitro osteoblastic differentiation and mineralization in primary bone marrow stromal cells. Tissue Eng 10: 16231632.
  • Byers BA, Guldberg RE, Hutmacher DW, Garcia AJ. 2006. Effects of Runx2 genetic engineering and in vitro maturation of tissue-engineered constructs on the repair of critical size bone defects. J Biomed Mater Res A 76: 646655.
  • Carano RA, Filvaroff EH. 2003. Angiogenesis and bone repair. Drug Discov Today 8: 980989.
  • Celeste AJ, Iannazzi JA, Taylor RC, Hewick RM, Rosen V, Wang EA, Wozney JM. 1990. Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. Proc Natl Acad Sci USA 87: 98439847.
  • Chhabra A, Zijerdi D, Zhang J, Kline A, Balian G, Hurwitz S. 2005. BMP-14 deficiency inhibits long bone fracture healing: a biochemical, histologic, and radiographic assessment. J Orthop Trauma 19: 629634.
  • Clarke SA, Hoskins NL, Jordan GR, Marsh DR. 2007. Healing of an ulnar defect using a proprietary TCP bone graft substitute, JAX, in association with autologous osteogenic cells and growth factors. Bone 40: 939947.
  • Conover CA. 2000. In vitro studies of insulin-like growth factor I and bone. Growth Horm IGF Res 10 ( Suppl B): S107S110.
  • Conover CA. 2008. Insulin-like growth factor-binding proteins and bone metabolism. Am J Physiol Endocrinol Metab 294: E10E14.
  • Dayoub H, Dumont RJ, Li JZ, Dumont AS, Hankins GR, Kallmes DF, Helm GA. 2003. Human mesenchymal stem cells transduced with recombinant bone morphogenetic protein-9 adenovirus promote osteogenesis in rodents. Tissue Eng 9: 347356.
  • Donahue RE, Kessler SW, Bodine D, McDonagh K, Dunbar C, Goodman S, Agricola B, Byrne E, Raffeld M, Moen R, Bacher J, Zsebo KM, Nienhuis AW. 1992. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 176: 11251135.
  • Dumont RJ, Dayoub H, Li JZ, Dumont AS, Kallmes DF, Hankins GR, Helm GA. 2002. Ex vivo bone morphogenetic protein-9 gene therapy using human mesenchymal stem cells induces spinal fusion in rodents. Neurosurgery 51: 12391244; discussion 1244–1235.
  • Egermann M, Baltzer AW, Adamaszek S, Evans C, Robbins P, Schneider E, Lill CA. 2006. Direct adenoviral transfer of bone morphogenetic protein-2 cDNA enhances fracture healing in osteoporotic sheep. Hum Gene Ther 17: 507517.
  • Feeley BT, Conduah AH, Sugiyama O, Krenek L, Chen IS, Lieberman JR. 2006. In vivo molecular imaging of adenoviral versus lentiviral gene therapy in two bone formation models. J Orthop Res 24: 17091721.
  • Fisher MC, Meyer C, Garber G, Dealy CN. 2005. Role of IGFBP2, IGF-I and IGF-II in regulating long bone growth. Bone 37: 741750.
  • Gan Y, Dai K, Zhang P, Tang T, Zhu Z, Lu J. 2008. The clinical use of enriched bone marrow stem cells combined with porous beta-tricalcium phosphate in posterior spinal fusion. Biomaterials 29: 39733982.
  • Gazit D, Turgeman G, Kelley P, Wang E, Jalenak M, Zilberman Y, Moutsatsos I. 1999. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy. J Gene Med 1: 121133.
  • Gugala Z, Olmsted-Davis EA, Gannon FH, Lindsey RW, Davis AR. 2003. Osteoinduction by ex vivo adenovirus-mediated BMP2 delivery is independent of cell type. Gene Ther 10: 12891296.
  • Hacein-Bey-Abina S, von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M. 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415419.
  • Hasharoni A, Zilberman Y, Turgeman G, Helm GA, Liebergall M, Gazit D. 2005. Murine spinal fusion induced by engineered mesenchymal stem cells that conditionally express bone morphogenetic protein-2. J Neurosurg Spine 3: 4752.
  • Helm GA, Alden TD, Beres EJ, Hudson SB, Das S, Engh JA, Pittman DD, Kerns KM, Kallmes DF. 2000. Use of bone morphogenetic protein-9 gene therapy to induce spinal arthrodesis in the rodent. J Neurosurg 92: 191196.
  • Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, Mueller E, Benjamin T, Spiegelman BM, Sharp PA, Hopkins N, Yaffe MB. 2005. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 309: 10741078.
  • Hou Z, Nguyen Q, Frenkel B, Nilsson SK, Milne M, van Wijnen AJ, Stein JL, Quesenberry P, Lian JB, Stein GS. 1999. Osteoblast-specific gene expression after transplantation of marrow cells: implications for skeletal gene therapy. Proc Natl Acad Sci USA 96: 72947299.
  • Hu J, Qi MC, Zou SJ, Li JH, Luo E. 2007. Callus formation enhanced by BMP-7 ex vivo gene therapy during distraction osteogenesis in rats. J Orthop Res 25: 241251.
  • Hurwitz DR, Kirchgesser M, Merrill W, Galanopoulos T, McGrath CA, Emami S, Hansen M, Cherington V, Appel JM, Bizinkauskas CB, Brackmann HH, Levine PH, Greenberger JS. 1997. Systemic delivery of human growth hormone or human factor IX in dogs by reintroduced genetically modified autologous bone marrow stromal cells. Hum Gene Ther 8: 137156.
  • Kumar S, Mahendra G, Nagy TR, Ponnazhagan S. 2004. Osteogenic differentiation of recombinant adeno-associated virus 2-transduced murine mesenchymal stem cells and development of an immunocompetent mouse model for ex vivo osteoporosis gene therapy. Hum Gene Ther 15: 11971206.
  • Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X, Binder GK, Slepushkin V, Lemiale F, Mascola JR, Bushman FD, Dropulic B, June CH. 2006. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 103: 1737217377.
  • Li JZ, Hankins GR, Kao C, Li H, Kammauff J, Helm GA. 2003. Osteogenesis in rats induced by a novel recombinant helper-dependent bone morphogenetic protein-9 (BMP-9) adenovirus. J Gene Med 5: 748756.
  • Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J, Forster M, Stocking C, Wahlers A, Frank O, Ostertag W, Kuhlcke K, Eckert HG, Fehse B, Baum C. 2002. Murine leukemia induced by retroviral gene marking. Science 296: 497.
  • Lieberman JR, Daluiski A, Stevenson S, Wu L, McAllister P, Lee YP, Kabo JM, Finerman GA, Berk AJ, Witte ON. 1999. The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am 81: 905917.
  • Lieberman JR, Le LQ, Wu L, Finerman GA, Berk A, Witte ON, Stevenson S. 1998. Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res 16: 330339.
  • Lou J, Xu F, Merkel K, Manske P. 1999. Gene therapy: adenovirus-mediated human bone morphogenetic protein-2 gene transfer induces mesenchymal progenitor cell proliferation and differentiation in vitro and bone formation in vivo. J Orthop Res 17: 4350.
  • Mankani MH, Kuznetsov SA, Shannon B, Nalla RK, Ritchie RO, Qin Y, Robey PG. 2006. Canine cranial reconstruction using autologous bone marrow stromal cells. Am J Pathol 168: 542550.
  • Marcacci M, Kon E, Moukhachev V, Lavroukov A, Kutepov S, Quarto R, Mastrogiacomo M, Cancedda R. 2007. Stem cells associated with macroporous bioceramics for long bone repair: 6- to 7-year outcome of a pilot clinical study. Tissue Eng 13: 947955.
  • Meiering CD, Linial ML. 2001. Historical perspective of foamy virus epidemiology and infection. Clin Microbiol Rev 14: 165176.
  • Meijer GJ, de Bruijn JD, Koole R, van Blitterswijk CA. 2007. Cell-based bone tissue engineering. PLoS Med 4: e9.
  • Mergia A, Heinkelein M. 2003. Foamy virus vectors. Curr Top Microbiol Immunol 277: 131159.
  • Merriman HL, van Wijnen AJ, Hiebert S, Bidwell JP, Fey E, Lian J, Stein J, Stein GS. 1995. The tissue-specific nuclear matrix protein, NMP-2, is a member of the AML/CBF/PEBP2/runt domain transcription factor family: interactions with the osteocalcin gene promoter. Biochemistry 34: 1312513132.
  • Moutsatsos IK, Turgeman G, Zhou S, Kurkalli BG, Pelled G, Tzur L, Kelley P, Stumm N, Mi S, Muller R, Zilberman Y, Gazit D. 2001. Exogenously regulated stem cell-mediated gene therapy for bone regeneration. Mol Ther 3: 449461.
  • Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrugghe B. 2002. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108: 1729.
  • Nilsson SK, Dooner MS, Weier HU, Frenkel B, Lian JB, Stein GS, Quesenberry PJ. 1999. Cells capable of bone production engraft from whole bone marrow transplants in nonablated mice. J Exp Med 189: 729734.
  • Nixon AJ, Goodrich LR, Scimeca MS, Witte TH, Schnabel LV, Watts AE, Robbins PD. 2007. Gene therapy in musculoskeletal repair. Ann N Y Acad Sci 1117: 310327.
  • Niyibizi C, Wang S, Mi Z, Robbins PD. 2004. The fate of mesenchymal stem cells transplanted into immunocompetent neonatal mice: implications for skeletal gene therapy via stem cells. Mol Ther 9: 955963.
  • Ohgushi H, Goldberg VM, Caplan AI. 1989. Repair of bone defects with marrow cells and porous ceramic. Experiments in rats. Acta Orthop Scand 60: 334339.
  • Olmsted-Davis EA, Gugala Z, Gannon FH, Yotnda P, McAlhany RE, Lindsey RW, Davis AR. 2002. Use of a chimeric adenovirus vector enhances BMP2 production and bone formation. Hum Gene Ther 13: 13371347.
  • Owen TA, Smock SL, Prakash S, Pinder L, Brees D, Krull D, Castleberry TA, Clancy YC, Marks SC, Jr., Safadi FF, Popoff SN. 2003. Identification and characterization of the genes encoding human and mouse osteoactivin. Crit Rev Eukaryot Gene Expr 13: 205220.
  • Park J, Ries J, Gelse K, Kloss F, von der Mark K, Wiltfang J, Neukam FW, Schneider H. 2003. Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. Gene Ther 10: 10891098.
  • Peng H, Chen ST, Wergedal JE, Polo JM, Yee JK, Lau KH, Baylink DJ. 2001. Development of an MFG-based retroviral vector system for secretion of high levels of functionally active human BMP4. Mol Ther 4: 95104.
  • Peng H, Wright V, Usas A, Gearhart B, Shen HC, Cummins J, Huard J. 2002. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 110: 751759.
  • Ploemacher RE, Engels LJ, Mayer AE, Thies S, Neben S. 1999. Bone morphogenetic protein 9 is a potent synergistic factor for murine hemopoietic progenitor cell generation and colony formation in serum-free cultures. Leukemia 13: 428437.
  • Prockop DJ. 1997. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276: 7174.
  • Quarto R, Mastrogiacomo M, Cancedda R, Kutepov SM, Mukhachev V, Lavroukov A, Kon E, Marcacci M. 2001. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med 344: 385386.
  • Riew KD, Lou J, Wright NM, Cheng SL, Bae KT, Avioli LV. 2003. Thoracoscopic intradiscal spine fusion using a minimally invasive gene-therapy technique. J Bone Joint Surg Am 85: 866871.
  • Rose T, Peng H, Shen HC, Usas A, Kuroda R, Lill H, Fu FH, Huard J. 2003. The role of cell type in bone healing mediated by ex vivo gene therapy. Langenbecks Arch Surg 388: 347355.
  • Rosen CJ. 2000. IGF-I and osteoporosis. Clin Lab Med 20: 591602.
  • Rundle CH, Miyakoshi N, Kasukawa Y, Chen ST, Sheng MH, Wergedal JE, Lau KH, Baylink DJ. 2003. In vivo bone formation in fracture repair induced by direct retroviral-based gene therapy with bone morphogenetic protein-4. Bone 32: 591601.
  • Schwarzwaelder K, Howe SJ, Schmidt M, Brugman MH, Deichmann A, Glimm H, Schmidt S, Prinz C, Wissler M, King DJ, Zhang F, Parsley KL, Gilmour KC, Sinclair J, Bayford J, Peraj R, Pike-Overzet K, Staal FJ, de Ridder D, Kinnon C, Abel U, Wagemaker G, Gaspar HB, Thrasher AJ, von Kalle C. 2007. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 117: 22412249.
  • Selim AA, Abdelmagid SM, Kanaan RA, Smock SL, Owen TA, Popoff SN, Safadi FF. 2003. Anti-osteoactivin antibody inhibits osteoblast differentiation and function in vitro. Crit Rev Eukaryot Gene Expr 13: 265275.
  • Shang Q, Wang Z, Liu W, Shi Y, Cui L, Cao Y. 2001. Tissue-engineered bone repair of sheep cranial defects with autologous bone marrow stromal cells. J Craniofac Surg 12: 586593; discussion 594–585.
  • Sugiyama O, Orimo H, Suzuki S, Yamashita K, Ito H, Shimada T. 2003. Bone formation following transplantation of genetically modified primary bone marrow stromal cells. J Orthop Res 21: 630637.
  • Suzuki K, Oyama M, Faulcon L, Robbins PD, Niyibizi C. 2000. In vivo expression of human growth hormone by genetically modified murine bone marrow stromal cells and its effect on the cells in vitro. Cell Transplant 9: 319327.
  • Terrovitis JV, Bulte JW, Sarvananthan S, Crowe LA, Sarathchandra P, Batten P, Sachlos E, Chester AH, Czernuszka JT, Firmin DN, Taylor PM, Yacoub MH. 2006. Magnetic resonance imaging of ferumoxide-labeled mesenchymal stem cells seeded on collagen scaffolds-relevance to tissue engineering. Tissue Eng 12: 27652775.
  • Thaller SR, Dart A, Tesluk H. 1993. The effects of insulin-like growth factor-1 on critical-size calvarial defects in Sprague-Dawley rats. Ann Plast Surg 31: 429433.
  • Tsuda H, Wada T, Ito Y, Uchida H, Dehari H, Nakamura K, Sasaki K, Kobune M, Yamashita T, Hamada H. 2003. Efficient BMP2 gene transfer and bone formation of mesenchymal stem cells by a fiber-mutant adenoviral vector. Mol Ther 7: 354365.
  • Tu Q, Valverde P, Li S, Zhang J, Yang P, Chen J. 2007. Osterix overexpression in mesenchymal stem cells stimulates healing of critical-sized defects in murine calvarial bone. Tissue Eng 13: 24312440.
  • Turgeman G, Pittman DD, Muller R, Kurkalli BG, Zhou S, Pelled G, Peyser A, Zilberman Y, Moutsatsos IK, Gazit D. 2001. Engineered human mesenchymal stem cells: a novel platform for skeletal cell mediated gene therapy. J Gene Med 3: 240251.
  • Varady P, Li JZ, Cunningham M, Beres EJ, Das S, Engh J, Alden TD, Pittman DD, Kerns KM, Kallmes DF, Helm GA. 2001. Morphologic analysis of BMP-9 gene therapy-induced osteogenesis. Hum Gene Ther 12: 697710.
  • Yang S, Wei D, Wang D, Phimphilai M, Krebsbach PH, Franceschi RT. 2003. In vitro and in vivo synergistic interactions between the Runx2/Cbfa1 transcription factor and bone morphogenetic protein-2 in stimulating osteoblast differentiation. J Bone Miner Res 18: 705715.
  • Zachos TA, Shields KM, Bertone AL. 2006. Gene-mediated osteogenic differentiation of stem cells by bone morphogenetic proteins-2 or -6. J Orthop Res 24: 12791291.
  • Zhang XS, Linkhart TA, Chen ST, Peng H, Wergedal JE, Guttierez GG, Sheng MH, Lau KH, Baylink DJ. 2004. Local ex vivo gene therapy with bone marrow stromal cells expressing human BMP4 promotes endosteal bone formation in mice. J Gene Med 6: 415.
  • Zhao G, Monier-Faugere MC, Langub MC, Geng Z, Nakayama T, Pike JW, Chernausek SD, Rosen CJ, Donahue LR, Malluche HH, Fagin JA, Clemens TL. 2000. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 141: 26742682.
  • Zhao Z, Wang Z, Ge C, Krebsbach P, Franceschi RT. 2007. Healing cranial defects with AdRunx2-transduced marrow stromal cells. J Dent Res 86: 12071211.
  • Zhao Z, Zhao M, Xiao G, Franceschi RT. 2005. Gene transfer of the Runx2 transcription factor enhances osteogenic activity of bone marrow stromal cells in vitro and in vivo. Mol Ther 12: 247253.
  • Zheng H, Guo Z, Ma Q, Jia H, Dang G. 2004. Cbfa1/osf2 transduced bone marrow stromal cells facilitate bone formation in vitro and in vivo. Calcif Tissue Int 74: 194203.
  • Zofkova I. 2003. Pathophysiological and clinical importance of insulin-like growth factor-I with respect to bone metabolism. Physiol Res 52: 657679.